Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Asia Diagnostics Summit 2018

Asia Diagnostics Summit 2018 Agenda


Print Agenda

Monday, 5 November 2018

08:00

Conference Registration, Materials Pick-Up, Morning Coffee, Tea and Breakfast Pastries


Session Title: Emerging Themes in Diagnostics, circa 2018

09:00

Takahiro OchiyaKeynote Presentation

Exosome Diagnosis Presents a Novel Platform for Liquid Biopsy
Takahiro Ochiya, Chief, National Cancer Center Research Institute Japan, Japan

Exosomes are 50-150 nm size in diameter extracellular vesicles (EVs) secreted by multiple living cells into the extracellular space. They contain tissue or cell-specific bioactive materials, including DNAs, mRNAs, ncRNAs, proteins, lipids, metabolites, etc. with their specific surface markers, such as, CD9, CD63, CD81, Alix, etc. Exosomes have been considered as information carriers in cell communication between cancer cells and non-cancer cells, which affect gene expressions and cellular signalling pathways of recipient cells by delivering their contents. Exosomes are promising tools for improving cancer care, but conversely may also contribute to tumor progression. Here, we highlight recently discovered roles of exosomes in modulating cancer microenvironment. We also discuss how exosomes could be exploited as biomarkers for a novel platform of liquid biopsy and delivery vehicles in cancer therapy.

09:45

Dominique PV de KleijnKeynote Presentation

Diagnostic Potential of Plasma Vesicles for Ischemic Heart Disease
Dominique PV de Kleijn, Professor Experimental Vascular Surgery, Professor Netherlands Heart Institute, University Medical Center Utrecht, The Netherlands, Netherlands

Cardiovascular Disease (CVD) is with the cardiovascular events of Ischemic Heart Disease and Stroke, the number 1 and 2 cause of death in the world and expect to increase especially in Asia. Ischemic heart disease (IHD) comprises 3 entities: stable coronary artery disease (SCAD), unstable angina (UA) and myocardial infarction (MI). Because IHD is associated with an increased risk of adverse clinical events such as heart failure and death, early recognition of IHD is of utmost importance. However, to diagnosis IHD is challenging, as many patients present with atypical symptoms. It is known that women have a different symptom sensation than men. Troponins are the main diagnostic tool for detection of MI. Blood biomarkers for SCAD (typically causing stable angina) and UA, however, are not available. These diagnoses frequently require hospital visits/admissions for time-consuming and costly (non)invasive tests. We use a protein signature measured  in 3 different subsets of plasma extracellular vesicle as an accurate source for early diagnosis of SCAD and UA. Diagnosis of ischemic heart disease as well as normalization and characterization of extracellular vesicles in plasma subfractions will be discussed.

10:30

Morning Coffee Break and Networking

11:15

Max MaKeynote Presentation

Early Assessment of Treatment Response in Solid Tumors via Quantitating Circulating Tumor DNA
Max Ma, Director, Medical Affairs, Roche Sequencing Solutions, Inc., United States of America

Thanks to the advancement of modern medicine, multiple therapeutic options often exist for the treatment of various cancers. Lessons learned from managing blood cancers under therapy have taught us the importance of early response. Longitudinal monitoring of circulating tumor DNA (ctDNA) is an emerging method for disease management in solid tumors. We employed a 197-gene NGS assay, the AVENIO ctDNA Surveillance Kit, which allowed us to perform longitudinal ctDNA analysis and measure changes in ctDNA levels in plasma. Specifically, we evaluated the association between change in ctDNA levels within first two cycles of treatment and survival data from a cohort of 106 advanced lung adenocarcinoma subjects treated with first-line chemo or chemoradiation therapies. Our data show that a decrease in post-treatment ctDNA level measured by the Surveillance Kit was associated with better outcome (both PFS and OS) in advanced lung adenocarcinoma. Thus, an early assessment of treatment effect can be measured using ctDNA in plasma within 1 or 2 treatment cycles.

12:00

Networking Lunch

14:00

Hsian-Rong TsengKeynote Presentation

NanoVelcro Rare-Cell Assays for Detection and Characterization of Circulating Tumor Cells
Hsian-Rong Tseng, Professor, Crump Institute for Molecular Imaging, California NanoSystems Institute, University of California-Los Angeles, United States of America

Circulating tumor cells (CTCs) are cancer cells shredded from either a primary tumor or a metastatic site and circulate in the blood as the potential cellular origin of metastasis. By detecting and analyzing CTCs, we will be able to noninvasively monitor disease progression in individual cancer patients and obtain insightful information for assessing disease status, thus realizing the concept of “tumor liquid biopsy”. Over the past decade, our research team at UCLA pioneered a unique concept of “NanoVelcro” cell-affinity substrates, in which CTC capture agent-coated nanostructured substrates were utilized to immobilize CTCs with remarkable efficiency. Five generations of NanoVelcro CTC assays have been developed over the past decade for a variety of clinical utilities, including CTC enumeration for prognosis and staging, single-CTC mutational analysis for tracking tumor origin, and CTC-based molecular analysis for treatment monitoring.  In this presentation, I will summarize the development of the new generations of NanoVelcro CTC assays and the clinical applications of these new diagnostic devices.

14:45

John BrennanKeynote Presentation

Integrating Aptamer Technology with Paper-Based Point-of-Care Devices for Biomedical Monitoring
John Brennan, Professor and Director, Biointerfaces Institute, McMaster University, Canada

DNA aptamers and DNA enzymes (denoted as functional nucleic acids or FNA) are an emerging platform for development of point-of-care (POC) diagnostic devices.  In this presentation, I will first focus on the development of new aptamers and DNA enzymes for a range of key biomarkers and their integration into colorimetric and fluorimetric assays for a variety of targets, mainly in the area of infectious disease.  Methods to couple target binding to FNAs to produce a DNA strand as an output, and to then use the output DNA to initiate isothermal amplification (ITA), will then be described.  Finally, the printing of specific “modules” for recognition (FNA), amplification (via ITA) and detection onto paper devices will be described as a way to generate a range of new POC devices that allow facile detection of a range of clinical analytes.  Examples will be provided to demonstrate multi-step reactions on paper for ultra-sensitive detection of E. coli, C. difficile, MRSA and H. pylori.

15:30

Afternoon Coffee Break

16:00

Balaji PanchapakesanKeynote Presentation

Liquid Biopsy Using the Nanotube-CTC-Chip
Balaji Panchapakesan, Professor, Department of Mechanical Engineering, Worcester Polytechnic Institute (WPI), United States of America

In the recent past, we reported the nanotube-CTC-chip for rapid classification of biomarkers using electrical signals and cell capture from droplets with 55-100% yield. In this talk, we will outline the further development of the nanotube-CTC-chip for highly efficient capture of CTCs with very high quality.  Advantages of the nanotube-CTC-chip include both positive and negative selection strategy on the same chip resulting in potential to capture invasive CTC phenotypes with diverse population of cells. The nanotube-CTC-chip also enables culturing of cancer cells directly on the device for further analysis. Potentially one can achieve capture of CTCs based on multiple biomarkers, negative selection by depleting leukocytes, and density gradient based selection of nucleated cells, thereby avoiding loss of CTCs due to variation in size and biomarker composition in a single blood test.

16:45

A Rapid and Mobile Fiber Optic Nanoplasmonic Biosensor
Lai-Kwan Chau, Professor, National Chung Cheng University, Taiwan

A rapid and mobile biosensing platform for low-cost point-of-care testing based on fiber optic nanoplasmonics, which takes advantage of the multiple total internal reflections in an optical fiber to offer superior detection limits.

17:15

Regulatory Challenges on Commercialization of Emerging Precision Medicine Technology-based Product
Ting-Shou Chen, Division Director, Industrial Technology Research Institute, Taiwan

After the announcement of precision medicine initiative in 2015, precision medicine has become an emerging research area, and in these years, a lot of companies aiming at this burgeoning around the world. Among these, some of them focus on diagnostic service or novel biomarker, but as the regulatory authority begins to eye on so called “LDT (Laboratory Developed Test)”, there will be some impacts on this emerging industry. This session explores some recent examples related to the strategies and implementation of precision medicine and the possible impact of regulation.

17:45

Close of Day 1 of the Conference.

Tuesday, 6 November 2018

09:00

Morning Coffee and Breakfast Pastries

09:30

MMI Microscope-based Single Cell IsolationIsolating Adherent Single Cells – The Taming of the Shrew
Chris Wetzel, Director of Sales and Marketing, MMI Microscope-based Single Cell Isolation

•    Applications: Why analyze single cells
•    Tools: How to precisely isolate a single cell
•    Case study: Isolating adherent single cells selectively

10:00

Moving Toward the Future in the Diagnosis of Infectious Diseases
Po-Yu Liu, Infectious Diseases Physician , Taichung Veterans General Hospital, Taiwan

Despite our socioeconomic advance today, humans remain vulnerable to infectious diseases, the leading causes of mortalities worldwide. Globalization and climate changes have driven re-distribution of emerging pathogens. The importance of the identification of causative organism cannot be overemphasized in infectious diseases, especially in light of the highly diverse nature of infectious diseases. However, conventional culture-based techniques are laborious, time-consuming and could be highly biased among batches. Rapid progress in development of sequencing technologies over past two decades, however, now allows us to identify microorganisms without being discouraged by inborn weakness of culture-based techniques. Metagenomics, a direct sequencing tool, characterizes genes and genomes that present in complex microbial ecosystems and offers us an access to understanding the vast unculturable species. With these emerging technologies, it time to open up a new chapter in clinical microbiology and infectious diseases.

10:30

From Clinical Testing to Large Scale Population Genetic Study
Shida Zhu, VP of Precision Medicine, BGI-Research, China

Non-invasive prenatal testing (NIPT) has grown to be one of the largest single IVD service in the market. More than 1 million tests are performed every year, generating big data of low pass whole genome sequencing. We analyze the NIPT data from 141,431 Chinese women, to characterize the population genetic structure and to investigate genetic associations with maternal and infectious traits. We show that the present day distribution of alleles is a function of both ancient migration and very recent population movements. We reveal novel phenotype-genotype associations, including several replicated associations with height and BMI, an association between maternal age and EMB, and be- tween twin pregnancy and NRG1. Finally, we identify a unique pattern of circulating viral DNA in plasma with high prevalence of hepatitis B and other clinically relevant maternal infections. These findings demonstrate the great value and potential of accumulating NIPT data for worldwide medical and genetic analyses.

11:00

Coffee and Tea Break

11:30

Using Molecular Beacons for Extracellular Vesicles and CTC-based Cancer Detection
James Lee, Helen C. Kurtz Professor of Chemical and Biomolecular Engineering, The Ohio State University, United States of America

Given their role in fundamental tumor biology, circulating non-coding RNAs and coding RNAs have emerged as potential biomarkers for cancer detection. Extracellular RNAs have been found to be stable in blood and other bodily fluids, partially attributable to their encapsulation within cell-secreted extracellular vesicles (EVs). The current method for EV analysis uses either PCR, next generation sequencing and/or hybridization microarray to identify the presence of RNA targets. These technologies involve breaking open all EVs in the sample to mix their contents, so they can only provide averaged information. Since EVs come from multiple cell sources, RNA targets of cancer cells derived EVs are diluted in these analyses. We have developed facile and inexpensive biochip technologies to detect target RNA using advanced molecular beacons designs and nanoparticles. These biochips technologies have been successfully applied to various cancer diagnosis in liquid biopsy. The molecular beacons can also be used to detect RNA targets in circulating tumor cells (CTCs) in blood.

12:00

Lunch

13:00

Visit to Taipei Academic Institution for Networking with Local Researchers

  • National Taiwan University Center of Genomics and Precision Medicine
  • Taipei Medical University Hospital: Biobank, ICU and Smart Hospital


Add to Calendar ▼2018-11-05 00:00:002018-11-06 00:00:00Europe/LondonAsia Diagnostics Summit 2018Asia Diagnostics Summit 2018 in Taipei, TaiwanTaipei, TaiwanSELECTBIOenquiries@selectbiosciences.com